-
公开(公告)号:US20240398826A1
公开(公告)日:2024-12-05
申请号:US18805254
申请日:2024-08-14
Applicant: Hoffmann-La Roche Inc.
Inventor: Patrick BUSSON , Georg HUMMEL , Thomas Peter Wilhelm KNOBLOCH
IPC: A61K31/551 , A61K9/16 , A61K9/28 , A61K9/50
Abstract: The invention relates to a pharmaceutical composition of 8-chloro-5-methyl-1-1-[4-(2-pyridyloxy)cyclohexyl]-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, a process for the preparation thereof and its use in the treatment of diseases. The pharmaceutical composition includes a tablet kernel consisting of a disintegrant, a filler, a glidant and a lubricant.
-
公开(公告)号:US20240383875A1
公开(公告)日:2024-11-21
申请号:US18777339
申请日:2024-07-18
Applicant: Hoffmann-La Roche Inc.
Inventor: Mahendra AWALE , Stefan BERCHTOLD , Julie CHARPENTIER , Héloïse Marie Albine COLOMBANO , Guillaume DECORET , Katrin GROEBKE ZBINDEN , Nicole GROSSMANN , Wolfgang HAAP , Philip Anthony HARRIS , Jérôme HERT , Jonah Milton KALLENBACH , Christian KRAMER , Lukas KREIS , Danny KRUMM , Xavier LUCAS CABRE , Nenad MANEVSKI , Philippe PFLIEGER , Amir Mohsen POURMOUSA ABKENAR , Etienne RAUBER , Dazhi TAN , Jean-Yves WACH , Roger WERMUTH
IPC: C07D401/14 , A61K9/00 , A61K9/20 , A61K9/28 , A61K9/48 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/538 , A61K47/10 , A61K47/12 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/107 , C07D498/04
Abstract: The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2′, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
-
公开(公告)号:US20240368309A1
公开(公告)日:2024-11-07
申请号:US18527135
申请日:2023-12-01
Applicant: Hoffmann-La Roche Inc.
Inventor: Stephan GASSER , Guy GEORGES , Thomas HOFER , Christian KLEIN , Ekkehard MOESSNER , Johannes SAM , Jenny Tosca THOM , Pablo UMANA , Tina WEINZIERL
Abstract: The present invention relates to bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28 comprising new humanized EpCAM antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
-
公开(公告)号:US20240358704A1
公开(公告)日:2024-10-31
申请号:US18627727
申请日:2024-04-05
Applicant: Hoffmann-La Roche Inc.
Inventor: Nicole HELLBACH , Heidemarie KLETZL , Friedrich METZGER , Renata SICILIANI SCALCO
IPC: A61K31/519 , A61K9/00 , A61K9/08 , A61K39/00 , A61K39/395 , A61P21/00
CPC classification number: A61K31/519 , A61K9/0053 , A61K9/0095 , A61K9/08 , A61K39/3955 , A61P21/00 , A61K2039/545
Abstract: The invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, also known as risdiplam, for use in the treatment of spinal muscular atrophy (SMA) with GYM329, its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
-
公开(公告)号:US12129304B2
公开(公告)日:2024-10-29
申请号:US16756057
申请日:2018-10-19
Applicant: F. Hoffmann-La Roche AG
Inventor: Michael Wenger , Mehrdad Mobasher , Chin-Yu Lin
CPC classification number: C07K16/2887 , A61K47/10 , A61K47/183 , A61P35/00 , A61K2039/505 , A61K2039/545 , A61K45/06
Abstract: The present disclosure relates to administration speed of obinutuzumab.
-
公开(公告)号:US12128103B2
公开(公告)日:2024-10-29
申请号:US18637283
申请日:2024-04-16
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Mark C. Benyunes , Graham Alexander Ross
IPC: A61K39/395 , A61K9/00 , A61K31/337 , A61K45/06 , A61P35/00 , C07K16/32 , A61K39/00
CPC classification number: A61K39/39558 , A61K9/0019 , A61K45/06 , A61P35/00 , C07K16/32 , A61K31/337 , A61K2039/507 , A61K2039/545 , A61K2300/00
Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
-
公开(公告)号:US12122791B2
公开(公告)日:2024-10-22
申请号:US17842612
申请日:2022-06-16
Applicant: Hoffmann-La Roche Inc.
Inventor: Jean-Michel Adam , Serena Maria Fantasia , Daniel Vincent Fishlock , Fabienne Hoffmann-Emery , Gerard Moine , Christophe Pfleger , Christian Moessner
IPC: C07D519/00 , B01J23/44 , B01J23/755
CPC classification number: C07D519/00 , B01J23/44 , B01J23/755
Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
-
公开(公告)号:US12116576B2
公开(公告)日:2024-10-15
申请号:US17130451
申请日:2020-12-22
Applicant: Hoffmann-La Roche Inc.
Inventor: Lykke Pedersen , Søren Rasmussen , Gianluigi Lichinchi , Christoffer Sondergaard
IPC: C12N15/113 , A61K47/54
CPC classification number: C12N15/1138 , A61K47/549 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/351
Abstract: The present invention relates to oligonucleotides (oligomers) that are complementary to voltage-gated sodium ion channel encoding nucleic acids, such as SCN9A, which encodes the voltage-gated sodium channel Nav1.7. The oligonucleotides of the invention are capable of inhibiting the expression of voltage-gated sodium ion channels, such as Nav1.7, and are useful in the prevention or the treatment of pain.
-
公开(公告)号:US20240331415A1
公开(公告)日:2024-10-03
申请号:US18294059
申请日:2022-08-10
Applicant: Hoffmann-La Roche Inc.
Inventor: Filippo ARCADU , Citlalli GAMEZ SERNA , Fernando ROMERO PALOMO
IPC: G06V20/69 , G06V10/774 , G06V10/776 , G06V10/80 , G06V10/82 , G06V20/70
CPC classification number: G06V20/698 , G06V10/774 , G06V10/776 , G06V10/806 , G06V10/82 , G06V20/695 , G06V20/70 , G06V2201/031
Abstract: A computer-implemented method of identifying a tissue type in digital histological images of human or animal tissue comprises training a convolutional neural network CNN to identify a particular target tissue type in a plurality of training data sets of digital histological images, inputting a test data set of digital histological images into the trained convolutional neural network, receiving as an output result of the convolutional neural network a probability value that the inputted test data set corresponds to the target tissue type. A training procedure of the CNN comprises performing with a plurality of training data sets the steps of selecting a target tissue area of the training data set, dividing the target tissue area into a different sets of tiles of constant size but having different image magnifications, inputting the sets of tiles into a multi-headed convolutional neural network, wherein the sets of tiles having different image magnifications are processed in parallel and the features of the sets of tiles are concatenated.
-
公开(公告)号:US20240325372A1
公开(公告)日:2024-10-03
申请号:US18618124
申请日:2024-03-27
Applicant: Hoffmann-La Roche Inc.
Inventor: Alessia FORNONI
IPC: A61K31/455 , A61K9/00 , A61P13/12
CPC classification number: A61K31/455 , A61K9/0053 , A61P13/12
Abstract: The present disclosure relates to ABCA1 inducer compounds for use in treating kidney disorders, and in particular, chronic kidney diseases, glomerular discases or proteinuric kidney diseases such as Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney discasc.
-
-
-
-
-
-
-
-
-